Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits.
Pratt
Raymond D
RD
Clinical Research, Eisai Incorporated, Glenpointe Centre West, 500 Frank W. Burr Boulevard, Teaneck, NJ 07666-6741, USA. ray_pratt@eisai.com
Perdomo
C A
CA
D000368:Aged; D000369:Aged, 80 and over; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects*; D015140:Dementia, Vascular / Q000188:drug therapy* / Q000523:psychology*; D000077265:Donepezil; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007189:Indans / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil